Recently, rivaroxaban tablets produced by Changzhou Pharmaceutical Factory Co., Ltd., a subsidiary of Shanghai Pharmaceuticals, received a drug registration certificate issued by the Thai Food and Drug Administration, and the drug has been approved for marketing.
Rivaroxaban tablets are primarily used to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation; to treat and prevent deep vein thrombosis (DVT); to treat pulmonary embolism (PE); and to prevent venous thromboembolism (VTE) in patients with acute illness. Rivaroxaban tablets were originally developed jointly by Bayer and Janssen and were launched in the United States in 2011.
In May 2025, Changzhou Pharmaceutical Factory's rivaroxaban tablets obtained approval from the U.S. Food and Drug Administration. In October 2025, it obtained a drug registration certificate in Malaysia, and in February 2026, it obtained a drug registration certificate in Singapore.
According to IQVIA database, the total sales of rivaroxaban tablets in the Thai market in 2025 were US$18.72 million across three specifications (10mg, 15mg, and 20mg).
The approval of the Thai Food and Drug Administration for the three specifications of rivaroxaban tablets (10mg, 15mg, and 20mg) signifies that the drug is now qualified for sale in Thailand, which will have a positive impact on the company's expansion into overseas markets and will accumulate valuable experience.

https://bydrug.pharmcube.com/news/detail/54cd479a0b8c19dd63dfd86ab5111e6a